Unknown

Dataset Information

0

Biomarkers of ketamine's antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology.


ABSTRACT: Major depressive disorder (MDD) is one of the leading causes of morbidity and all-cause mortality (including suicide) worldwide, and, unfortunately, first-line monoaminergic antidepressants and evidence-based psychotherapies are not effective for all patients. Subanesthetic doses of the N-methyl-D-aspartate receptor antagonists and glutamate modulators ketamine and S-ketamine have rapid and robust antidepressant efficacy in such treatment-resistant depressed patients (TRD). Yet, as with all antidepressant treatments including electroconvulsive therapy (ECT), not all TRD patients adequately respond, and we are presently unable to a priori predict who will respond or not respond to ketamine. Therefore, antidepressant treatment response biomarkers to ketamine have been a major focus of research for over a decade. In this article, we review the evidence in support of treatment response biomarkers, with a particular focus on genetics, functional magnetic resonance imaging, and neurophysiological studies, i.e. electroencephalography and magnetoencephalography. The studies outlined here lay the groundwork for replication and dissemination.

SUBMITTER: Alario AA 

PROVIDER: S-EPMC8186113 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9320296 | biostudies-literature
| S-EPMC5694011 | biostudies-literature
| S-EPMC5157762 | biostudies-literature
| S-EPMC7269589 | biostudies-literature
| S-EPMC10899278 | biostudies-literature
| S-EPMC8358579 | biostudies-literature
| S-EPMC5546993 | biostudies-literature
| S-EPMC10216051 | biostudies-literature
| S-EPMC8032870 | biostudies-literature
| S-EPMC6915079 | biostudies-literature